THE estimated 33,000 Australians living with moderately to severely active ulcerative colitis (UC) will be pleased to learn that Federal Health Minister Greg Hunt has announced the PBS funding of Janssen's Simponi (golimumab) under certain eligibility criteria, effective 01 Jun.
Simponi works by targeting elevated levels of tumour necrosis factor (TNF), a protein which is overproduced in those living with UC, resulting in chronic inflammation.
The product is administered by subcutaneous injection every four weeks.
See the PI at janssen.com.
The above article was sent to subscribers in Pharmacy Daily's issue from 30 May 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 30 May 18
